Spot Gold Nearly Erases All Gains for the Year
Svmuu News On Monday, spot gold once fell to $4,320.30 per ounce—just over a dollar higher than its price at the end of last year, nearly erasing all gains for the year. Meanwhile, the war in the Middle East has entered its fourth week, with new threats of attacks exchanged between the United States and Iran. Since the conflict began, rising oil prices have increased inflation risks and reduced the likelihood of the Federal Reserve and other central banks cutting interest rates in the short term. This is a negative factor for gold, which has fallen for eight consecutive trading days and just recorded its largest weekly decline since 1983. Kyle Rodda, an analyst at Capital.com, stated that due to technical reasons, "gold is expected to rebound in the short term," which largely depends on "whether Trump can follow through on his threat to attack Iran's power plants." (Jin10)
Source:Odaily · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
24H Trending
-
1
Billionaire investor Chase Coleman’s Tiger Global fund disclosed in its latest 13F filing that its top five growth stocks are all focused on AI infrastructure, including TSMC, NVIDIA, Amazon, Meta, and Google.
-
2
Analysis of CRYSTAL’s Value and Investment Potential: An Examination of Multiple Projects and Risk Assessment
-
3
Will the BEAM token go to zero? Could it rise to $1,000? An in-depth analysis of the Beam network and its market prospects
-
4
What Is CVP? An In-Depth Analysis of the PowerPool Ecosystem and the Investment Value of Its Token, CVP
-
5
The analysis points out that Iran’s overlapping centers of power complicate efforts to end the war with the United States, and that the Revolutionary Guards possess significant operational autonomy.
-
6
Analysis: The State Street Healthcare ETF (XLV) has an expense ratio of 0.08% and a diversified portfolio, while the Invesco Biotechnology ETF (PBE) has an expense ratio of 0.58% and focuses on small-cap stocks; PBE is up 10.2% year-to-date, outperforming XLV.
-
7
What Is JGN? Analysis of the JGN (Sword Saint Coin) Project’s Positioning, Features, and Value
-
8
QUARTZ Coin Analysis: An Overview of the Sandclock (QUARTZ) and Unique Network’s Quartz (QTZ) Projects
-
9
Ethereum Recent Rebound: Price Breaks Above $1,970, but Multiple Risks Remain
-
10
Analysis Compares Healthcare ETFs: Invesco Nasdaq Biotech ETF (IBBQ) Saw 45.5% One-Year Return, Outperforming State Street Healthcare Select Sector SPDR ETF (XLV)
Markets Today
Recommended Reading








